37 results
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
, $488,000 in employee compensation, $141,000 in stock-based compensation and $92,000 in insurance expenses. These changes were offset by increases
424B4
CNSP
Cns Pharmaceuticals Inc
31 Jan 24
Prospectus supplement with pricing info
4:27pm
expenses, $29,000 in insurance expenses and $68,000 in stock compensation and $6,000 in other general and administrative expenses, which were offset … compensation, $117,000 in legal and professional expenses, and $69,000 in insurance expenses, which were offset by increases of approximately $112,000
8-K
EX-99.1
6h3pse
14 Aug 23
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Continued rapid pace of enrollment with ~75% of expected patients now enrolled
9:25am
8-K
EX-99.1
tkbjl
15 May 23
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides
8:36am
8-K
EX-99.1
n2p7vobmnrh522x2 1kb
15 Aug 22
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9:09am
8-K
EX-99.1
p7esiipzmbgs2z
16 May 22
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:38pm